Quantum Cyber N.V. (MYNZ) Form 10-Q — May 15, 2026
Quantum Cyber N.V. (formerly Mainz Biomed) reported a net loss of $5.1 million for Q1 2026, citing a material weakness in internal controls and raising substantial doubt about its ability to continue as a going concern due to an accumulated deficit of $110 million. The company executed a strategic pivot, exiting its colorectal cancer business by selling the ColoAlert and NextGen intellectual property for approximately $1.6 million in total proceeds, while terminating all employees in its German subsidiary.
Key figures
- Revenue
- 0
- Total Debt
- 3128665
- Cash Position
- 4752966
- Proceeds preferred
- 6000000
- Severance payments
- 1900000
- Shares outstanding
- 14661169
- Accumulated deficit
- 109984357
- Proceeds ordinary atm
- 2088238
- Preferred shares issued
- 3000000
- Ordinary shares issued q1
- 1735194
- Asset sale proceeds nextgen
- 1250000
- Asset sale proceeds coloalert
- 348966
- License agreement value bp united
- 5000000
Price after filing
Close on the filing date to close N calendar days later (from $3.49). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.